Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation

Andrea Marcellusi1,2 | Francesco Saverio Mennini1,2 | Murad Ruf3 | Claudio Galli4 | Alessio Aghemo5,6 | Maurizia R. Brunetto7,8 | Sergio Babudieri9 | Antonio Craxi10 | Massimo Andreoni11,12 | Loreta A. Kondili13

1Economic Evaluation and HTA (EEHTA), CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy
2Institute of Leadership and Management in Health, Kingston Business School, Kingston University, London, UK
3Public Health, Medical Affairs, Gilead Science, London, UK
4Global Medical and Scientific Affairs, Core Laboratory, Abbott, Rome, Italy
5Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
6Division of Internal Medicine and Hepatology, Humanitas Research Hospital IRCCS, Rozzano, Italy
7Internal Medicine, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
8Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, University Hospital of Pisa, Pisa, Italy
9Infectious and Tropical Disease Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
10Gastroenterology and Hepatology Unit, Department of Internal Medicine and Medical Specialties "PROMISE", University of Palermo, Palermo, Italy
11Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
12Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy
13Center for Global Health, Istituto Superiore di Sanità, Rome, Italy

Correspondence
Loreta A. Kondili, Center for Global Health, Istituto Superiore di Sanità, Viale Regina Elena, Rome, Italy.
Email: loreta.kondili@iss.it

Funding information
This work has been funded by Gilead Sciences Italy. Content, conclusions and recommendations were agreed by consensus by the authors. The funder of the study had no involvement in study design, in final model structure, in the literature data collection, data analysis, data interpretation or writing of the report.

Handling Editor: Luca Valenti

Objective:
Optimized diagnostic algorithms to detect active infections are crucial to achieving HCV elimination. We evaluated the cost effectiveness and sustainability of different algorithms for HCV active infection diagnosis, in a context of a high endemic country for HCV infection.

Methods: A Markov disease progression model, simulating six diagnostic algorithms in the birth cohort 1969–1989 over a 10-year horizon from a healthcare perspective was used. Conventionally diagnosis of active HCV infection is through detection of antibodies (HCV-Ab) detection followed by HCV-RNA or HCV core antigen (HCV-Ag) confirmatory testing either on a second sample or by same sample reflex testing. The undiagnosed and unconfirmed rates were evaluated by assays false negative estimates and each algorithm patients’ drop-off. Age, liver disease stages distribution, liver disease stage costs, treatment effectiveness and costs were used to evaluate
1 | INTRODUCTION

Chronic viral hepatitis C is a major public health problem. Achieving the WHO’s Global Health Sector Strategy (GHSS) goals for the elimination of Hepatitis C virus (HCV) by 2030 has reinvigorated public health initiatives aimed at identifying patients with HCV related disease. Italy is one of the countries with the greatest burden of HCV in Western Europe. Up to now, more than 220,000 patients have been treated with Direct Acting Antivirals (DAAs), which are estimated as 40%-60% of infected individuals, the remaining are estimated at least 280,000 individuals mostly unaware of their HCV active infection. In order to achieve HCV elimination by 2030 Italy, like many other countries, will need to succeed in tackling the undiagnosed proportion of infected individuals. The Italian Governative “Milleproroghe Decree”, through an amendment approved in March 2020, has allocated €71.5 million for the period 2020-2022 to introduce free-of-charge screening for the general population born between 1969 and 1989, as well as all individuals at public specialist facilities for drug addiction and prisons. Although the screening budget has been established, optimisation along the entire patient pathway is necessary to achieve elimination by 2030. Crucially, high enough coverage level for treatment in the first instance also depends on optimized diagnostic pathways to confirm active infection. In order to realize an effective screening strategy and to overcome challenges on the adherence, simple diagnostic paths to avoid losing substantial shares of patients with active infections has been proposed by the scientific community.

The aim of this study was to evaluate the cost-effectiveness of different diagnostic algorithms for active HCV infection including conventional two steps algorithms and same sample reflex testing (single step) combined with modelling treatment impacts and disease progression in order to provide for a complete overview of diagnostic costs and benefits.

2 | METHODS

The primary outcome measure of screening effectiveness was the number of active infections diagnosed. An adapted multicohort Markov model (Figure S1) capturing multiple states of morbidity and mortality was used to evaluate the HCV disease progression and related costs for linked-to-care patients vs those not linked over a 10-year time horizon (years 2020-2030).
We compared strategies in terms of the total costs of screening according to each diagnostic algorithm and treatment costs of active HCV infection vs the disease costs of those not diagnosed over time. We considered the Italian general population birth cohort (1969-1989) screening. The model inputs are shown in Tables 1 and 2.

2.1 | Model structure

The model starts with a decision probabilistic tree that simulates HCV testing in the general population cohort born between years 1969-1989 with a coverage rate of 70% (approximately 12,000,000 individuals eligible for testing). This first part of the model identified, categorized, and evaluated all patients with an active HCV infection that could be potentially diagnosed by each screening option. Each strategy in the decision tree considers the detection of HCV antibodies (HCV-Ab) results and in case of positive test the confirmation of active infection through HCV-RNA or HCV core antigen (HCV-Ag) testing either by conventional two steps or reflex testing (single step). We have considered the following definitions:

1. Active infection is defined as the presence of markers of viral replication in chronic infection state.
2. ‘Reflex testing’ means that HCV-RNA of HCV-Ag is performed on the same serological specimen with a positive anti-HCV finding. If the reflex test is positive, an active HCV infection is diagnosed and the patient will be referred for disease staging and treatment.9
3. “Undiagnosed” cases were defined as having active HCV infection but with HCV-Ab false negative results, or false negative confirmation test following an anti-HCV positive test result.17-20
4. “Unconfirmed” active infection was defined as HCV-Ab positive without confirmation of active infection.
5. In both undiagnosed and unconfirmed groups, individuals with active infection will not be linked to care following the first HCV-Ab test (Figure 1).

In the simulations, we considered six alternative diagnostic algorithms (1a to 3b) for diagnosis of active HCV infection. In each scenario, the initial screening is performed through an assay for HCV-Ab, either rapid or laboratory (phlebotomy) based, followed by confirmation through HCV-RNA or HCV-Ag testing (laboratory based). Four of these scenarios require two visits for confirmation of active HCV infection with subsequent patient referral, while the remaining two require only one visit (Figure 2). Based on previous published reports we assumed the drop-off of patients from the first visit for antibody detection and the second visit for confirmatory testing to be 45% (ranges 36%-54%).16,22

2.2 | Transition probabilities

Table 1 summarizes the available information regarding the different screening strategies considered in the decision tree. The Markov model considered published transition probabilities previously used in the same modelling (Table S1).12,13

Disease progression depends on the linkage to care probabilities12,13 and the previously estimated Fibrosis stage (F, graded from 1 to 4) at the time of the diagnosis.14 Throughout annual cycles, patients could remain in their current liver disease stage or progress to a worse state according to the natural history of the disease or stopped/slowed down liver disease progression by HCV elimination by treatment (patients with confirmed active infection linked to care and cure). An immediate linkage to care following the diagnosis of an active infection diagnosis and its consequences over a period of 10 years (up to 2030) was assumed for each screening strategy.

Individuals with undiagnosed or unconfirmed infection were considered as not being linked to care. Therefore, these individuals were assumed to either progress according to the natural history of disease until 2030 or diagnosed because of complications of cirrhosis (1 year later for F4 fibrosis stage and 4 years later for F3 fibrosis stage that progress to cirrhosis). Unconfirmed and undiagnosed F0-F2 fibrosis also progress according to the natural history of the disease until the year 2030. After these periods, the model assumes that all patients were diagnosed and treated. For unscreened individuals, the model assumes progression according to the natural disease history.

2.3 | Epidemiological and clinical parameters

The model assumes a fibrosis distribution for the diagnosed patients through screening as it is reported in our previous studies, based on infection and disease burdens for yet to be treated patients.5,14 For screened but undiagnosed or unconfirmed (see definitions above) individuals the distribution of fibrosis from F0 to F3 (asymptomatic) was made at the time of modelling start and F4 were excluded on the assumption of being diagnosed by screening as the diagnosis should be done due to a symptomatic disease (cirrhosis) (Table 1).

2.4 | Efficacy: SVR rates

The efficacy of second-generation DAA regimens used in the Markov Model, was considered 98%9 and was stratified by the presence or absence of cirrhosis (F0-F4, DC, or HCC (Table S2). F0-F3 does not progress furthermore following viral eradication whereas in F4/DC or HCC a slow progression after HCV eradication was considered.

2.5 | Cost of screening and HCV health states

The decision tree model considers only the unit price related to the first-line test (HCV-Ab), the cost of administration of the first-line test and the tariff associated with the second line tests (Table 2).

Direct healthcare costs were those associated with DAAAs and the management of HCV-related diseases. The average and range of
| Decision Tree epidemiological parameters | Base-case | Min | Max | Sources |
|----------------------------------------|-----------|-----|-----|---------|
| Population born 1969-1989*             | 16,978,388| 12,733,791 | 21,222,985 | ISTAT. Resident Population, By Age. 2020. dati. istat.it. Accessed 17/10/2020. |
| Screening coverage rate                 | 70%       | 53% | 88% | Assumption |
| Number of prevalent undiagnosed HCV patient | 115,000 | 86,250 | 143,750 | Estimations from [14] |
| % of prevalent undiagnosed HCV patient | 0.7%      | 0.5% | 0.8% | Calculation |

1.a) Rapid Ab assay +confirmation (RNA)
- Ab HCV+/HCV RNA-: 0.30% 0.24% 0.36% [15]
- Unconfirmed: 45.00% 36.00% 54.00% [16]
- Undiagnosed: 7.50% 6.00% 9.00% False Negative 1st and 2nd line test (7% for anti-HCV [17,18]; 0.5% for HCV-RNA – assumption)

1.b) Rapid Ab assay +confirmation (Ag)
- Ab HCV+/HCV Ag-: 0.30% 0.24% 0.36% [15]
- Unconfirmed: 45.00% 36.00% 54.00% [16]
- Undiagnosed: 10.50% 8.40% 12.60% False Negative 1st and 2nd line test (7% for anti-HCV [17,18]; 3.5% for HCV-Ag [19])

2.a) Lab-based Ab assay +confirmation (RNA) with second sample taken
- Ab HCV+/HCV RNA-: 0.30% 0.24% 0.36% [15]
- Unconfirmed: 45.00% 36.00% 54.00% [16]
- Undiagnosed: 2.50% 2.00% 3.00% False Negative 1st and 2nd line test (2% for anti-HCV [20]; 0.5% for HCV-RNA – assumption)

2.b) Lab-based Ab assay +confirmation (Ag) with second sample taken
- Ab HCV+/HCV Ag-: 0.30% 0.24% 0.36% [15]
- Unconfirmed: 45.00% 36.00% 54.00% [16]
- Undiagnosed: 5.50% 4.40% 6.60% False Negative 1st and 2nd line test (2% for anti-HCV [20]; 3.5% for HCV-Ag [21])

3.a) Lab-based Ab assay +confirmation (RNA) reflex testing
- Ab HCV+/HCV RNA-: 0.30% 0.24% 0.36% [15]
- Unconfirmed: 17.00% 13.60% 20.40% [16]
- Undiagnosed: 2.50% 2.00% 3.00% False Negative 1st and 2nd line test (2% for anti-HCV [20]; 0.5% for HCV-RNA – assumption)

3.b) Lab-based Ab assay +confirmation (Ag) reflex testing
- Ab HCV+/HCV Ag-: 0.30% 0.24% 0.36% (15)
- Unconfirmed: 17.00% 13.60% 20.40% (16)
- Undiagnosed: 5.50% 4.40% 6.60% False Negative 1st and 2nd line test (2% for anti-HCV [20]; 3.5% for HCV-Ag [21])

Fibrosis distribution of patients that are undiagnosed
- F0-F2: 75% 56% 94% [5,14]
- F3: 20% 15% 25% [5,14]
- F4: 5% 4% 6% [5,14]
- DC+HCC: 0% 0% 0% [5,14]

Fibrosis distribution of patients that are Unconfirmed/Unlinked to care
- F0-F2: 75% 56% 94% [5,14], Assumption
- F3: 20% 15% 25% [5,14]
- F4: 5% 4% 6% [5,14]
- DC+HCC: 0% 0% 0% [5,14], Assumption
costs (MIN– MAX) of HCV-related liver disease were derived from the literature (Table 2).\textsuperscript{12,21} The average treatment cost of DAAs was estimated based on expert opinion and non-official previously well-validated sources.\textsuperscript{14} Costs were expressed in Euros and were discounted at a rate of 3% annually.

### 2.6 | Model outcomes

Health outcomes were expressed in terms of quality-adjusted life-years (QALYs) incorporating mortality and morbidity associated with a particular health state. Utilities were associated with each health state and a full health condition was assumed for undiagnosed individuals. The model considers in the base-case the same utilities previously reported and used in our modelling studies on HCV treatment (Table 2).\textsuperscript{21} QALYs were discounted by an annual rate of 3%.

### 2.7 | Incremental cost-effectiveness analysis

Strategies were compared using incremental cost-effectiveness ratios (ICERs), calculated as the additional cost divided by the additional health benefit of the alternative with lower QALYs or compared with the Standard of Care (SoC) (Figure 1, testing option 2a), and expressed as the cost per QALY gained. We used the commonly cited Italian willingness-to-pay (WTP) threshold of €25,000/QALY.\textsuperscript{23} Outcome measures were assessed from a healthcare sector perspective.

### 2.8 | Multivariate sensitivity analysis

We performed deterministic sensitivity analyses (DSA) to identify parameters with the greatest impact on cost-effectiveness. We considered one-way variations (Table 1 and 2) and calculated the corresponding ICER estimated for the reflex approach vs the SoC (HCV-Ab first than confirmatory HCV-RNA or HCV-Ag test with two visit approach) for these parameters:

1. Tests sensitivity and specificity
2. Ability on linking to care
3. All HCV tests’ costs (HCV-Ab, HCV-RNA and HCV-Ag costs)
4. Other direct costs (healthcare costs related to chronic liver disease)
5. Health status utilities

Probabilistic Sensitivity Analysis (PSA) was performed considering a gamma distribution for costs and beta distribution for epidemiological parameters.\textsuperscript{21} During PSA, values were varied widely within the ranges stated in Tables 1 and 2, and were randomly sampled from the respective distributions with 5,000 Monte Carlo simulations. Based on these simulations, the cost-effectiveness acceptability curve (CEAC) for the best cost-effective scenario vs lower efficacy screening option and second most effective screening alternative were presented.

### 3 | RESULTS

The screening costs for different options evaluated varied from €60.5 million to €66.2 million with higher costs in algorithms that contain HCV-RNA test for confirmation vs the HCV-Ag (Table 3). An increasing trend of treatment costs on reflex testing vs other options has been estimated, ranging from €414.1 million to €464.7 million (Table 3). This reflects the higher number of treated patients according to each screening strategy, being highest in the reflex (3a and 3b) vs the algorithms that require two visits for the detection of HCV active infection.
The comparison of cost effectiveness results is based considering as reference the option which produces the lowest QALYs. As shown in Table 4, the reference is option 1b (Rapid Ab assays + confirmation HCV-Ag).

All ICERs estimated are far below the WTP threshold. The lowest ICER is estimated for the HCV-Ag reflex testing; however, in a range of cost effective options (varying from €2,211-862/QALY) the best option is given by the HCV-RNA reflex testing in that it produces the highest QALYs (974,458) or the highest incremental QALYs (107,623) vs the reference (1b) option which is the least effective option. Comparing reflex vs two steps diagnostic algorithms a persistent increase in QALYs with a very low ICERs varying from €566-635 per QALYs is estimated (Table 4).

**TABLE 2 Decision tree and markov model parameters**

| First Line Test | Decision tree | Markov model |
|-----------------|---------------|--------------|
| Base-case | Min | Max | SE | Base-case | Min | Max | SE | Source |
| Ab Essay | € 5 | € 4 | € 6 | € 1 | Law Reimbursed |
| Administration Rapid Ab Essay | € 3 | € 2.4 | € 3.6 | € 1 | Assumption |
| Administration Ab Essay (Second Sample or Reflex) | € 5 | € 4 | € 6 | € 1 | Italian Ministerial Decree (18 October 2012) |
| RNA confirmatory test | € 68.35 | € 54.68 | € 82.02 | € 10 | Italian Ministerial Decree (18 October 2012) |
| Ag confirmatory test | € 15.85 | € 12.68 | € 19.02 | € 13 | Assumption |
| Cost of treatment | | | | Source |
| Treatment Cost | € 6,000.00 | € 4,800.00 | € 7,200.00 | € 1,000.00 | Assumption by local experts |
| Other direct medical costs | Base-case | Min | Max | SE | Source |
| F0 | € 234 | € 176 | € 292 | € 25 | [13] |
| F1 | € 234 | € 176 | € 292 | € 25 | [13] |
| F2 | € 234 | € 176 | € 292 | € 25 | [13] |
| F3 | € 617 | € 292 | € 942 | € 139 | [13] |
| F4 | € 876 | € 397 | € 1,354 | € 205 | [13] |
| DC | € 6,627 | € 4,385 | € 8,868 | € 962 | [13] |
| HCC | € 12,896 | € 5,792 | € 20,000 | € 3,049 | [13] |
| Transplant (procedure) | € 73,774 | € 62,648 | € 84,900 | € 4,775 | [13] |
| Transplant (following years) | € 2,365 | € 0 | € 4,729 | € 1,015 | [13] |
| SVR to F0-F3 states | € 0 | € 0 | € 0 | € 0 | [13] |
| SVR to ILD states† | € 1,440 | € 397 | € 2,483 | € 448 | [13] |
| Health state | Utilities | | | Source |
| Base-case | Min | Max | SE | Source |
| F0 | 0.82 | 0.4 | 1.0 | -- | [21] |
| F1 | 0.82 | 0.4 | 1.0 | -- | [21] |
| F2 | 0.82 | 0.4 | 1.0 | -- | [21] |
| F3 | 0.82 | 0.4 | 1.0 | -- | [21] |
| F4 | 0.78 | 0.4 | 1.0 | -- | [21] |
| DC | 0.65 | 0.3 | 1.0 | -- | [21] |
| HCC | 0.25 | 0.1 | 0.4 | -- | [21] |
| Transplant (procedure) | 0.5 | 0.3 | 0.7 | -- | [21] |
| Transplant (following years) | 0.7 | 0.4 | 1.0 | -- | [21] |
| SVR to F0-F3 states | 1 | 0.5 | 1.0 | -- | [21] |
| SVR to ILD states† | 0.91 | 0.5 | 1.0 | -- | [21] |

Note: Abbreviations: Ab, Antibodies; Ag, Antigen; DC, Decompensated Cirrhosis; HCC, Hepatocellular Carcinoma; ILD, Irreversible Liver Disease (F4, DC and HCC); RNA, Ribonucleic Acid; SE, Standard Error; SVR, Sustained Virologic Response.
The deterministic sensitivity analysis (Figure 3) shows that the most sensitive parameters of the model are represented by the variation of the utilities associated with the disease states (a 25% variation causes an ICER increase of one third times higher than the base-case), 1st and 2nd line test costs (25% variation causes ±17% of the ICER value) and other direct costs (±8% of variation for the corresponding ICER).

**Figure 1** Decision tree model scheme. Option 1: HCV-Ab by rapid assay on oral or blood specimen followed by (1.a) second sample serum/plasma testing for HCV-RNA or (1b) serum/plasma HCV-Ag. Option 2: HCV-Ab by a laboratory-based assay on serum/plasma followed by (2a) second sample serum/plasma testing for HCV-RNA or (2b) serum/plasma HCV-Ag. Option 3: HCV Ab on serum/plasma by a laboratory-based assay followed by same sample reflex testing for (3a) HCV-RNA or (3b) HCV-Ag (3b) on the initial sample. Abbreviations: Ab, Antibodies; Ag, Antigen; HCV, Hepatitis C Virus; RNA, Ribonucleic Acid

**Figure 2** Patient journey to HCV active infection diagnosis. Abbreviations: HCV, Hepatitis C Virus
Probabilistic sensitivity analysis confirmed that the reflex approach compared to the SoC would be cost-effective for >90% of simulations at a minimum WTP threshold of €1,000/QALY gained and for >99.9% of simulation at a maximum WTP threshold of €25,000/QALY gained (Figure 4A). Most points on the cost-effectiveness plane (Figure 4B) are distributed in the northeast quadrant, showing that reflex approach was associated with higher costs and greater benefits than SoC. In some cases, reflex is dominant if compared with SoC (<5% of the simulation in the southeast quadrant).

4 | DISCUSSION

In the general population, only 40%-70% of HCV-Ab positive individuals have an active infection, requiring confirmation by HCV-RNA or HCV-Ag. To date in Italy and other developed countries, traditionally most diagnostic settings use a two-step (two visits) approach including a phlebotomy antibody test in step one and HCV-RNA confirmation in step two. Traditional approaches that include several steps in the diagnostic process often lead to incomplete diagnosis.

This is the first economic analysis that evaluates the cost-effectiveness profile of different diagnostic strategies aimed at maximising HCV elimination efforts. The key finding of our study is that reflex testing, even if more expensive in terms of screening and overall treatment costs, also achieved the highest number of confirmed infections and therefore associated QALYs (health benefit) compared to two step testing strategies within a 10 year time horizon (up to 2030).

Importantly these results suggest that despite the highest screening cost, HCV-RNA reflex is the most cost effective strategy.

| TABLE 3 | Base-case cost results (Italy – assuming a 70% coverage rate) |
| --- | --- | --- | --- | --- |
|  | Screening cost | Screening administration cost | Treatment cost | Disease cost |
| 1.b - Rapid Ab assay +confirmation (Ag) | € 60,553,442 | € 35,654,615 | € 414,125,853 | € 319,713,702 |
| 1.a - Rapid Ab assay +confirmation (RNA) | € 64,458,378 | € 35,654,615 | € 418,340,715 | € 321,028,714 |
| 2.b - Lab-based Ab assay +confirmation (Ag) with second sample taken | € 60,617,239 | € 59,424,358 | € 421,150,624 | € 321,905,388 |
| 2.a - Lab-based Ab assay +confirmation (RNA) with second sample taken | € 64,733,486 | € 59,424,358 | € 425,365,486 | € 323,220,400 |
| 3.b - Lab-based Ab assay +confirmation (Ag) reflex testing | € 60,974,298 | € 59,424,358 | € 460,489,341 | € 334,178,830 |
| 3.a - Lab-based Ab assay +confirmation (RNA) reflex testing | € 66,274,095 | € 59,424,358 | € 464,704,203 | € 335,493,841 |

Note: Abbreviations: Ab, Antibodies; Ag, Antigen; RNA, Ribonucleic Acid.

| TABLE 4 | Base-case cost-effectiveness |
| --- | --- | --- | --- | --- | --- | --- |
|  | Overall Cost | QALYs | ICER vs less effective option | ICER Reflex vs SoC |
|  | Inc QALYs | Inc Cost | ICER | Inc QALYs | Inc Cost | ICER |
| 1.b - Rapid Ab assay +confirmation (Ag) | € 830,047,612 | 866,835 | – | – | – | – |
| 1.a - Rapid Ab assay +confirmation (RNA) | € 839,482,421 | 875,803 | 8,969 | € 9,434,809 | € 1,052 | – | – | – |
| 2.b - Lab-based Ab assay +confirmation (Ag) with second sample taken | € 863,097,608 | 881,782 | 14,948 | € 33,049,996 | € 2,211 | – | – | – |
| 2.a - Lab-based Ab assay +confirmation (RNA) with second sample taken (SoC) | € 872,743,730 | 890,751 | 23,916 | € 42,696,118 | € 1,785 | – | – | – |
| 3.b - Lab-based Ab assay +confirmation (Ag) reflex testing | € 915,067,026 | 965,489 | 98,654 | € 85,019,414 | € 862 | 74,738 | € 42,323,296 | € 566 |
| 3.a - Lab-based Ab assay +confirmation (RNA) reflex testing | € 925,896,498 | 974,458 | 107,623 | € 95,848,886 | € 891 | 83,707 | € 53,152,768 | € 635 |

Note: Abbreviations: Ab, Antibodies; Ag, Antigen; ICER, Incremental Cost-Effectiveness Ratio; Inc, Incremental; QALY, Quality-Adjusted Life Years, RNA, Ribonucleic Acid; SoC, Standard of Care.
Our findings suggest that the reflex testing should become the standard of care for the diagnosis of active HCV infection in both public and private laboratories. From a public health perspective, the real-world utility of HCV reflex testing at population level is also demonstrated in a recent cost-effectiveness analysis on routine universal HCV screening in urban emergency departments in England.24 In Italy, based on WHO and EASL recommendations reflex testing is already explicitly included in the recommendations of Italian Ministry of Health free of charge screening law decree.7,25 However, its implementation at Regional level has not yet been realized. The findings of this study will serve as evidence to increase the awareness of regional stakeholders, including medical and non-medical staff involved in the screening process to optimize the patient pathways for active HCV infection.

Our study has been tailored to the Italian context but the reflex testing strategies in detecting the active infection has proven effective also in other countries.24-28 We believe that the structure and findings of our model are well-suited for other countries who have ongoing or soon to be started high volume testing programmes to address HCV elimination as defined by the WHO.1 Without an active screening there will be a progressive decrease in diagnosed cases and few countries may be able to reach the mortality reduction endpoint.6,29,30 Broader screening for HCV would likely be cost-effective, but significantly reducing HCV-related morbidity and mortality would also require improved rates of referral, treatment and cure and this care cascade starts with maximizing the detection of active infection. Reflex testing, as outlined in our evaluation and in line with other recommendations,9-11 promises to be the most cost effective screening algorithm in terms of maximizing detection of active infection as first step into the HCV care cascade.

Within the two reflex testing strategies the use of HCV-Ag assay is not widespread in Italy, however, we feel that its inclusion in our cost-effectiveness analysis is justified for completeness, especially as our findings suggest that reflex testing with HCV-Ag compared to conventional two step testing could prove useful for high volume screening in countries where HCV-RNA testing is not available or affordable.9

In some settings HCV-Ab point of care testing has been shown to reduce time between the initial observation and treatment administration.9 We have demonstrated that this approach, though attractive for outreach screening for special populations, subsequently requires referral for conventional phlebotomy confirmation of active infection and was the less cost-effective option out of the six screening pathways analysed.

Health state utilities, costs of screening tests and direct medical costs had the highest impact on the ICER of reflex testing compared to the (two step) SoC. However, the highest ICER (resulting from the
lowest reported utilities) was less than €800/QALY, far lower than
the WTP threshold. Based on the simultaneous variations of the pa-
rameters evaluated by the PSA analysis, reflex testing although more
expensive than the two steps testing, remained highly cost effective
in 99.9% of the scenarios and dominant in 5%, which indicates less
costs sustained and higher efficacy for reflex vs the two step SoC
diagnostic algorithm.

The strength of our study is that using a specifically designed
Markov model of liver disease progression enables the evaluation of
the relative costs of screening, treatment and overall disease costs,
which change according to the proportion of undiagnosed patients
assumed, based on data from real life studies. Specifically, in a pro-
spective study a substantial drop off rate of 45% occurred at the
second visit for confirmatory serum/plasma testing, when the two
steps diagnostic algorithm was applied. In contrast, the introd-
uction of reflex testing and warning messages for referral resulted in
reduction in drop- off rate to just 17% with associated increase in the
number of patients diagnosed with active infection and therefore
evaluated for viral eradication by antiviral treatment. Other studies
reported that in the DAA era, 27%-68% of infected patients reached
the stage of confirmed infection. Based on these data, in our
analysis we assumed an increase of the proportion of individuals
with the diagnosis of active infection by reflex testing as compared
with the two steps approach.

The first and main limitation of this study is the assumption
for drop-off rate for each scenario. Reports are scarce, therefore
in the absence of Italian data we had to extrapolate from recent
estimates reported in the literature. Further in our analysis
we considered 70% uptake for HCV screening as it was reported
for other screening campaigns in Italy. As we examined a general
population birth cohort (not more challenging specialist popu-
lations) we feel that this uptake assumption is justified. We assumed
immediate linkage to care following the active infection diagnosis
for the 10 year period (up to 2030). Even if optimistic, this could
be achievable within the traditional healthcare system and serves
to highlight the need for continuous improvement of the entire

patient pathway. Finally, we considered only direct diagnostic assay costs for our study. However, the reduction of healthcare visits and associated additional staff and patients costs would likely further increase the cost-effectiveness estimates of the reflex testing strategy.

These screening algorithms are suggested only for general population unaware of chronic HCV infection. As the frequency of acute infection in general population without apparent risk factors is likely very low at population level in Italy and other developed countries, we did not consider diagnosis of acute infection in this evaluation. Different diagnostic algorithms should also be evaluated for marginalized populations.

In conclusion, our findings suggest same sample reflex testing, using either HCV-RNA or HCV-Ag, is the most cost effective diagnostic algorithm for countries wanting to embark on high volume HCV testing. Our data confirm the EASL and WHO guidelines recommending reflex testing as best practice in identifying HCV active infection in general population as compared to the other screening approaches. In line with the Italian Ministry of Health HCV screening recommendation, reflex testing should be adopted by the regional Italian health authorities as standard of care for the HCV diagnostic pathway.

CONFLICT OF INTEREST
Andrea Marcellusi has nothing to disclose; Francesco S. Mennini received advisor/speaker/research grants from Abbvie, MSD, Gilead, BMS; Maurizia R Brunetto received advisor/Speaker grants from AbbVie, Gilead, Janssen, Roche, EISAI-MSD and is Coordinator of the control room for the application of the Resolution n.397 April 2018 of the Tuscany Government for the control of chronic hepatitis C; Loreta A. Kondili received Speaker grants from Abbvie and Gilead. Murad Ruf is an employee of Gilead. Claudio Galli is employed by and owns stocks from Abbott.

GUARANTOR OF THE ARTICLE
The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

DATA AVAILABILITY STATEMENT
Data sharing is not applicable as no new data were generated/ the article describes entirely theoretical research.

ORCID
Andrea Marcellusi https://orcid.org/0000-0002-3974-3798
Francesco Saverio Mennini https://orcid.org/0000-0002-4738-5505
Claudio Galli https://orcid.org/0000-0002-0804-0387
Alessio Aghemo https://orcid.org/0000-0003-0941-3226
Maurizia R. Brunetto https://orcid.org/0000-0001-8364-9152
Sergio Babudieri https://orcid.org/0000-0001-7291-8687
Antonio Craxi https://orcid.org/0000-0002-4480-9544
Massimo Andreoni https://orcid.org/0000-0002-3205-9758
Loreta A. Kondili https://orcid.org/0000-0003-2656-224X

REFERENCES
1. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021 [Internet]. 2016. Available from: https://apps.who.int/iris/bitstream/10665/246177/1/WHO-HIV-2016.06-eng.pdf?ua=1 Accessed March 20 2021
2. European Centre for Disease Prevention and Control. Systematic review on hepatitis B and C prevalence in the EU/E EA [Internet]. 2016. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/systematic-review-hepatitis-B-C-prevalence.pdf Accessed March 20 2021
3. Deuuff–Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European Countries. Gastroenterology. 2012;143:974–985.e14.
4. The Italian Medicines Agency. AIFA Agenzia Italiana del Farmaco [Internet]. Agenziafarmaco.gov.it. 2021. Available from: https://www.aifa.gov.it/-/aggiornamento-epatite-c Accessed March 27 2021
5. Kondili LA, Andreoni M, Alberti A, et al. Estimated prevalence of undiagnosed HCV infected individuals in Italy: a mathematical model by route of transmission and fibrosis progression. Epidemics. 2021;34:100442.
6. Kondili L, Robbins S, Blach S, et al. Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach elimination goals? Liver Int. 2018;38:2109–2198.
7. Kondili LA, Aghemo A, Andreoni M, et al. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: from free-of-charge screening to regional roadmaps for an HCV-free nation. Digestive and Liver Disease. 2021;51590-8658.00142.
8. Feld J, Hepatitis C. Virus diagnostics: the road to simplification. Clin Liv Dis. 2018;12:125–129.
9. Pawlotsky J-M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: final update of the series. J Hepatol. 2020;73:1170–1218.
10. Chapko MK, Dubour DRobert, Hatia RI, et al. Cost-effectiveness of strategies for testing current hepatitis C virus infection. Hepatology. 2015;62:1396–1404.
11. Know your hepatitis status – increasing access to testing for a hidden infection [Internet]. Who.it. 2016. Available from: https://www.who.int/en/news-room/feature-stories/detail/know-your-hepatitis-status-increasing-access-to-testing-for-a-hidden-infection Accessed April 03 2021
12. Marcellusi A, Viti R, Kondili LA, et al. Economic consequences of investing in anti-HCV antiviral treatment from the italian nhs perspective: a real-world-based analysis of PITER data. Pharmacoeconomics. 2019;37(2):255–266.
13. Mennini FS, Marcellusi A, Robbins Scott S, et al. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries. Liver Int. 2021;41:934–948.
14. Kondili LA, Gamkrelidze I, Blach S, et al. Optimization of hepatitis C virus screening strategies by birth cohort in Italy. Liver Int. 2020;40:1545–1555.
15. Westbrook R, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:558–568.
16. Casas MDLP, Garcia F, Freyre-Carrillo C, et al. Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia. Revista Española De Enfermedades Digestivas. 2020;112:515–519.
17. Tang W, Chen W, Aminì A, et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. BMC Infect Dis. 2017;17:695.
18. Chionne P, Madonna E, Villano U, et al. Sensitivity of hepatitis C virus rapid tests in detecting antibodies in general population. Panminerva Med. 2020;62:125–130.
19. Freiman JM, Wang J, Easterbrook PJ, et al. Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset. J Hepatol. 2019;71:62–70.
20. Cadieux G, Campbell J, Dendukuri N. Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection. CMAJ Open. 2016;4:E737–E745.

21. Kondili LA, Romano F, Rolli FR, et al. Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort. *Hepatology*. 2017;66:1814–1825.

22. Jülicher P, Chulanov V, Pimenov N, et al. Streamlining the cascade for active Hepatitis C in Russia: a cost-effectiveness analysis. *PLoS One*. 2019;14:e0219687.

23. Fattore G. Associazione Italiana di Economica Sanitaria. Proposta di linee guida per la valutazione economica degli interventi sanitari. *PharmacoEconom Italian Res Art*. 2009;11:83–93.

24. Kondili LA, Aghemo A, Andreoni M. Challenges on the achievement of World Health Organization goals for HCV elimination in Italy: need for a Regional programmatic approach on screening and linkage to care. *Annali Dell’Istituto Superiore Di Sanità*. 2021;57:201–204.

25. Williams J, Vickerman P, Douthwaite S, et al. An economic evaluation of the cost-effectiveness of opt-out hepatitis B and hepatitis C testing in an emergency department setting in the United Kingdom. *Value Health*. 2020;23:1003–1011.

26. Huang C-F, Wu P-F, Yeh M-L, et al. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. *Clin Mol Hepatol*. 2021;27:136–143.

27. Evans H, Balasegaram S, Douthwaite S, et al. An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department. *PLoS One*. 2018;13:e0198520.

28. Vallejo A, Moldes LM, Trigo M, et al. Implementación generalizada del diagnóstico en un solo paso (DUSP) de la hepatitis C en Galicia: resultados para la reflexión. *Enferm Infecc Microbiol Clin*. 2021. https://doi.org/10.1016/j.eimc.2020.12.019

29. Gamkrelidze I, Pawlotsky J-M, Lazarus JV, et al. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis. *Liver Int*. 2021;41:456–463.

30. Kondili L, Craxì A, Aghemo A. Absolute targets for HCV elimination and national health policy paradigms: foreseeing future requirements. *Liver Int*. 2021;41:649–655.

31. Mera J, Vellozzi C, Hariri S, et al. Identification and clinical management of persons with chronic hepatitis C virus infection – cherokee nation, 2012–2015. *MMWR Morb Mortal Wkly Rep*. 2016;65:461–466.

32. Djuric O, Massari M, Ottone M, et al. Hepatitis C virus cascade of care in the general population, in people with diabetes, and in substance use disorder patients. *Infectious Agents and Cancer*. 2021;16:5.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Marcellusi A, Mennini FS, Ruf M, et al. Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation. *Liver Int*. 2022;42:26–37. doi:10.1111/liv.15070